Use of a clostridial toxin to reduce appetite

• US 20040253274A1
• Filed: 06/11/2003
• Published: 12/16/2004
• Est. Priority Date: 06/11/2003
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Voet, Martin A.
• Application Number:
  US10/459,767
• Publication Number:
  US 20040253274A1
• Time in Patent Office: Days
• US Class Current: 424/239.1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for reducing appetite by oral administration of a Clostridial toxin, such as a botulinum toxin.

Claims

1. A method for inhibiting secretion of Ghrelin by a stomach cell, the method comprising the step of administration of a botulinum toxin to a stomach cell capable of secreting Ghrelin, thereby inhibiting the secretion of Ghrelin from the stomach cell.

2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, F and G.

3. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

4. The method of claim 1, wherein the administration step comprises the step of oral ingestion of the botulinum toxin.

5. The method of claim 1, wherein within 10 days after administration of the botulinum toxin the plasma level of the Ghrelin in a plasma sample from a patient to which the botulinum toxin was administered is less than 100 fmol per ml of the patient'"'"'s plasma.

6. A method for inhibiting secretion of Ghrelin by a stomach cell, the method comprising the step of oral ingestion of a botulinum toxin type A to a Ghrelin secreting stomach cell thereby inhibiting the secretion of Ghrelin from the stomach cell.

7. A method for inhibiting release of growth hormone from a pituitary cell, the method comprising the step of administration of a botulinum toxin to a stomach cell capable of secreting Ghrelin, thereby reducing the secretion of Ghrelin from the stomach cell and inhibiting release of growth hormone from a pituitary cell.

8. The method of claim 7, wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, F and G.

9. The method of claim 8, wherein the botulinum toxin is a botulinum toxin type A.

10. The method of claim 9, wherein the administration step comprises the step of oral ingestion of the botulinum toxin.

11. The method of claim 10, wherein the botulinum toxin is administered in a therapeutically effective amount.

12. A method for reducing appetite, the method comprising the step of oral administration of a, botulinum toxin, thereby reducing appetite.

13. The method of claim 12, wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, F and G.

14. The method of claim 12, wherein the botulinum toxin is a botulinum toxin type A.

15. The method of claim 12, wherein the administration step comprises the step of oral ingestion of the botulinum toxin to reduce release of Ghrelin from a stomach cell.

16. The method of claim 12, wherein the botulinum toxin is administered in a therapeutically effective amount.

20. The method of claim 12, wherein the botulinum toxin is a botulinum toxin type A.

17. A method for reducing appetite, the method comprising the step of oral administration of a botulinum toxin type A to a stomach cell capable of secreting Ghrelin, thereby inhibiting the secretion of Ghrelin from the stomach cell and reducing appetite.

18. A method for reducing appetite, the method comprising the step of oral administration of a botulinum toxin, wherein the botulinum toxin is orally administered in an amount sufficient to reduce secretion of Ghrelin by a stomach cell, but in an amount insufficient to cause symptoms of systemic toxicity to the botulinum toxin.

19. The method of claim 18, wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, F and G.